Tirzepatide.

Dual GIP/GLP-1 agonist — broader metabolic effect than GLP-1 mono-agonists.

Select strengthPer-vial price

Quantity

Total

€120.00· 1 vial

Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.

✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
✓Patient-named prescription only — dispensed against a valid Rx.
✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
✓Cold-chain shipping across EU/EEA — 2–5 working days.

Overview

About Tirzepatide.

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors and the active ingredient of Mounjaro / Zepbound. The SURPASS programme established its glycemic and weight effects in type 2 diabetes; the SURMOUNT programme established its weight effects in obesity.

The dual incretin mechanism explains the larger weight effect observed in head-to-head comparisons with Semaglutide. As with any GLP-1 family molecule, careful titration is required to minimise GI side effects.

Mechanism of action

Tirzepatide is a 39-amino-acid synthetic peptide that activates both the GIP receptor and the GLP-1 receptor. GIP-receptor activation augments β-cell insulin secretion and modulates adipose-tissue lipid handling; GLP-1-receptor activation contributes glycemic control and central appetite suppression. The combined effect on metabolism is greater than either receptor pathway alone.

Posology · for information only

Subcutaneous injection, once weekly. Initiated at 2.5 mg with monthly titration steps to a maintenance dose typically between 5 and 15 mg per week.

Your physician sets the prescription. This is descriptive information, not a self-administration guide.

Storage

Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.

Evidence baseClinical RCT evidence

Indications studied

Type 2 diabetesObesityMetabolic syndrome

Selected references

01Jastreboff AM, et al. — Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med · 2022 · doi: 10.1056/NEJMoa2206038

Identification & specifications

INN / Name: Tirzepatide
Form: Lyophilised vial · subcutaneous injection
Strength: 5mg vial
Manufacturing: EU-GMP Annex 1 · Grade A/B
Endotoxins: European Pharmacopoeia 2.6.14 · LAL assay
Identity & purity: HPLC + MS · > 98%
Cold chain: Validated 2–8 °C, monitored end-to-end
Regulatory basis: Directive 2001/83/EC · Article 5(1)

Logistics

2–5 working days

EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.

Legal status

Magistral preparation

Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.

Cross-border

EU prescription recognition

Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.

Same therapeutic axis

Within Weight Management.

All Weight Management preparations